Search Results

Financial Assistance Resources WATCH Watch "Navigating Health & Disability Insurance" with Joanne Fawzy Morales, Esq. READ Read our blog post on Insurance Resources RESOURCES Boehringer Ingelheim created a resource designed to educate patients on the recent Medicare Part D changes. Click here to learn more. Advanced Accelerator Applications (AAA) has a patient support program to deliver assistance for eligible patients. Click here to learn more. GoodRx is a free website and mobile app that compares prescription drug price and provides drug coupons for discounts on medications. IpsenCares provides coverage, access, reimbursement, and education support for lanreotide (Somatuline Depot). Go to ipsencares.com or call 866-435-5677. Novartis Patient Assistance Foundation (NPAF) provides access to Novartis medications including Afinitor (everolimus), Lutathera (lutetium Lu177 dotatate), and Sandostatin LAR (octreotide acetate). Click here to check eligibility and application instructions. For the Novartis universal co-pay program, go to Copay.NovartisOncology.com or call 877-577-7756. Novartis - Patient Financial Assistance & Government Insurance TerSera offers co-pay assistance for Xermelo (telotristat ethyl), a prescription pill, used along with somatostatin analog (SSA) therapy for carcinoid syndrome diarrhea in adults who are not adequately controlled by SSA therapy. For more information, go to copay.xermelo.com. Patient Advocate Foundation provides co-pay relief and financial aid. Triage Cancer offers a lengthy list of financial resources including travel expenses and lodging, transportation, young adult specific assistance, prescription drugs, and much more. Neuroendocrine Cancer Awareness Network - Patient Financial Assistance Healthwell Foundation NeedyMeds NCI Travel and Lodging Reimbursement Info Packet Creon Financial Assistance The CureNET Project is offering a $5,000 patient grant for any NET patient that is 18 years or older. It is meant to help cover medical costs, travel to see a NET specialist, pay bills, allow families to spend time together - whatever the recipient feels necessary. The submission deadline is October 15, 2023. Click here for more information. The HealthWell Foundation® , an independent non-profit charitable organization that provides financial assistance for underinsured Americans has launched a new fund to assist individuals living with neuroendocrine tumors. Through the fund, HealthWell will provide up to $15,000 in medication copayment or insurance premium assistance to patients for prescription drugs and biologics for the treatment of their disease. Eligible patients must have household incomes up to 500 percent of the federal poverty level. To determine eligibility and apply for assistance, visit HealthWell's Neuroendocrine Tumors Fund page. Note that all new fund openings and fund re-openings occur at 11:00 a.m. Eastern Daylight Time (8:00 a.m. Pacific) Monday through Friday. For more information go to: https://www.healthwellfoundation.org/fund/neuroendocrine-tumors/ . Transportation Resources

Exelixis is innovating at the forefront of cancer care. Their comprehensive approach is powered by a broad array of diverse biotherapeutics and small molecule programs for the treatment of cancer exploring multiple modalities and mechanisms of action. Learn more at https://www.exelixis.com/. 2025 ANNUAL PATIENT CONFERENCE Confirm Your Visit to the Exelixis Virtual Booth! First name Last name Email Submit This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by NCF. Talk to your medical team about your individual care and treatment.

Lantheus is a leading radiopharmaceutical-focused company with proven expertise in developing, manufacturing and commercializing cutting-edge radiodiagnostics. Learn more about Lantheus's pipeline of radiopharmaceuticals for neuroendocrine tumors: https://www.lantheus.com/pipeline/ Submit Your Question for Lantheus 2025 ANNUAL PATIENT CONFERENCE Confirm Your Visit to the Lantheus Virtual Booth! First name Last name Email Submit This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by NCF. Talk to your medical team about your individual care and treatment.

Learn more about the NET experts presenting on various topics during the 2023 LACNETS Neuroendocrine Tumor Patient Conference. 2023 LACNETS + PPA + NCI Patient Conference Speakers SURGERY 101 FOR NETS JAMES HOWE, MD Professor of Surgery Director, Surgical Oncology and Endocrine Surgery Roy J. and Lucille A. Carver University of Iowa College of Medicine Dr. Howe is Professor of Surgery at the University of Iowa. He trained in General Surgery at Barnes Hospital/Washington University, which included a T32 Surgical Oncology research fellowship where he was a member of the group that found the gene responsible for Multiple Endocrine Neoplasia type 2 by positional cloning. He completed a clinical fellowship in Surgical Oncology at Memorial Sloan-Kettering Cancer Center, then began his career at the University of Iowa in 1996. Here he has specialized in gastrointestinal cancer and endocrine surgery, and his research has concentrated on genetic studies of cancer. His laboratory discovered a gene that causes the inherited colorectal cancer syndrome Juvenile Polyposis in 1998, and in 2001 identified a second predisposition gene. Dr. Howe has written over 170 peer-reviewed papers, one book, and over 50 book chapters. He has directed the Division of Surgical Oncology and Endocrine Surgery since 2002, and his clinical practice and research has focused on small bowel and pancreatic neuroendocrine tumors (NETs) and their metastases. Dr. Howe served as President of the North American Neuroendocrine Tumor Society from 2018-20 and the Society of Surgical Oncology from 2020-21. Clinically he is known for his work on cytoreduction of NET liver metastases and guidelines for the surgical management of small bowel and pancreatic NETs. Dr. Howe has directed a funded laboratory over his career, been chair of an NIH Study Section, and his current research focuses on gene expression and drug sensitivity in NETs. SURGERY: GI NETS ALEXANDRA GANGI, MD Surgical Oncologist Cedars-Sinai Medical Center Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. SURGERY: PNETS CALLISIA CLARKE, MD Chief of Surgical Oncology Medical College of Wisconsin Dr. Callisia Clarke completed her medical degree at the University of Cincinnati College of Medicine where she was elected to the Alpha Omega Alpha Honors Society. She completed a general surgery residency at the University of Cincinnati Medical Center in Cincinnati, Ohio in 2013 and a fellowship in Complex General Surgical Oncology at The University of Texas MD Anderson Cancer Center in 2016. She joined the faculty at the Medical College of Wisconsin in 2016 and is an Associate Professor of Surgery, and Chief of the Division of Surgical Oncology. Her research efforts are centered on epigenetic regulation of pancreatic neuroendocrine tumors and Diversity, Equity, and Inclusion in academic surgery. She holds several leadership positions in national organizations. She was recently elected the President-Elect of the Association for Academic Surgery, the first Black Woman to hold this office. And serves in other leadership roles in the Society of Surgical Oncology and the American Board of Surgery. SURGERY: LIVER NETS JONATHAN HERNANDEZ Chief of Surgical Oncology National Cancer Institute Dr. Hernandez graduated from medical school with honors from the University of Florida, and completed general surgery training at the University of South Florida. During his residency, Dr. Hernandez spent two years at the Moffitt Cancer Center and Research Institute interrogating molecular diagnostics for liver metastases and miRNA-mediated mechanisms of metastatic spread with the support of NIH funding. Following residency, Dr. Hernandez completed fellowship training in both surgical oncology and hepatopancreatobiliary surgery at Memorial Sloan Kettering Cancer Center. During his fellowships, Dr. Hernandez spent an additional two years in dedicated basic research studying metastatic colonization as a scholar in the Cell Biology Program of the Sloan Kettering Institute supported by NIH funding and a grant from America’s HepatoPancreatoBiliary Association. Dr. Hernandez was also a visiting investigator in the Cell and Developmental Biology Department of Weill Medical College of Cornell University studying metastatic niche evolution with funding support from the Conquer Cancer Foundation of the American Society of Clinical Oncology. Dr. Hernandez has authored over 150 peer-reviewed publications and has contributed book chapters in numerous authoritative surgical textbooks. Dr. Jonathan Hernandez is a surgical oncologist/HPB surgeon, chief of the surgical oncology section (Surgical Oncology Program/NCI/NIH), an Associate Professor of Surgery (Uniformed Services University of the Health Sciences), and a Clinical Professor of Surgery (George Washington University). He specializes in the treatment of metastatic and primary tumors of the liver, bile ducts and pancreas, as well as in the surgical management of complex abdominal tumors. Dr. Hernandez’s research efforts focus on implementation of ex-vivo human tumor systems that allow his lab to fully characterize tumors from the operating room and evaluate new therapies in an unfettered platform. The Hernandez lab utilizes these human tumor systems to 1) develop combination therapies for recalcitrant tumors, 2) delineate and target uncharacterized signaling axes for therapeutic gain in patients with cholangiocarcinoma, and 3) elucidate the mechanisms through which tumor cells coopt the microenvironment of distant organs to form life-threatening metastases. SURGERY: UNDERSTANDING CARCINOID CRISIS JULIE HALLET, MD, MSc, FRCSC, FSSO Associate Professor of Surgery Sunnybrook Health Sciences Center Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors, as well as minimally invasive therapies for cancer treatment. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet holds leadership roles in National and International societies. Among those roles, she serves as the Vice-Chair of the Hepato-Pancreatico-Biliary Disease Site Group of the Society of Surgical Oncology, the Chair of the Early Career Group the International Hepato-Pancreatico-Biliary Association, and a member of the Guidelines Committee of the North American Neuroendocrine Tumors Society, as well as on the executive committees of the Canadian Society of Surgical Oncology and the Canadian Hepato-Pancreato-Biliary Association. She is a founding member of the Society of Surgical Ergonomics for which she also chairs the Research and Applied Ergonomics Committee. She also is Associate Section Editor for the Annals of Surgical Oncology, and is part of the Editorial Board of HPB, the World Journal of Surgery, and the British Journal of Surgery. Dr. Hallet’s research focuses on health services research to examine processes of care and outcomes in oncology, with a focus on patient-centred and patient-reported outcomes. To support her research, she has received over $10 millions in operating grants, including from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research. Dr. Hallet has over 200 peer-reviewed publications, including high-impact papers in JAMA Surgery, JAMA Oncology, the Journal of the NCCN, and Annals of Surgery. THE ROLE OF NEOADJUVANT/ADJUVANT TREATMENT: DO I START SSA OR CHEMO BEFORE OR AFTER SURGERY? HELOISA SOARES, MD Medical Oncologist Associate Professor Huntsman Cancer Institute, University of Utah Dr. Heloisa Soares is a medical oncologist with a focus in GI and neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at University of Utah. Dr. Soares received her medical degree at Faculdade de Medicine do ABC in Brazil, where she was born. She completed her residency training at the Mount Sinai Medical Center of Florida and her hematology-oncology fellowship training and PhD in molecular biology at UCLA. Dr. Soares has neuroendocrine tumors and gastrointestinal (GI) cancers as the major focus of her research and clinical activities. She serves as the Medical Director for the Clinical Trials Office as well as the co-physician leader in the GI Clinical Trials Research Group at HCI. In 2019, she was elected as a member of the board of directors for The North American Neuroendocrine Tumor Society (NANETS). Additionally, she is a member of the NCI NET taskforce and member of SWOG and NRG cooperative groups. She is also a panel member for the Neuroendocrine and Adrenal Tumors NCCN Clinical Practice Guidelines in Oncology. MEDICAL 101 FOR NETS SANDY KOTIAH, MD Director, The Neuroendocrine Tumor Center Mercy Medical Center Sandy D. Kotiah, M.D., a Board Certified medical oncologist, serves as the Director of The Neuroendocrine Tumor Center at Mercy and is a member of Medical Oncology and Hematology at Mercy in Baltimore, Maryland. Dr. Kotiah leads a multidisciplinary team of specialty doctors focused on providing some of the best treatment options for rare neuroendocrine diseases. Dr. Kotiah’s compassionate and caring nature as well as her exceptional clinical knowledge and dedication to searching for answers to complicated cancer diagnoses makes her a sought-after Medical Oncologist and Hematologist in the Baltimore region. SYSTEMIC TREATMENTS - WHAT, WHEN & WHY OF MEDICAL THERAPIES (11:40 AM) WHAT'S NEW WITH PRRT: CLINICAL TRIALS (2:20 PM) AMAN CHAUHAN, MD Medical Oncologist University of Miami Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer Institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. NUTS & BOLTS OF CLINICAL TRIALS JAYDIRA DEL RIVERO, MD Endocrinologist and Oncologist National Cancer Institute Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. PRRT: WHAT PATIENTS NEED TO KNOW ERIK MITTRA, MD, PhD Radiologist, Nuclear Medicine Oregon Health & Science University Dr. Mittra is a Professor of Diagnostic Radiology at Oregon Health & Science University (OHSU) where he serves as Chief of the Molecular Imaging and Therapy Section and Director of the Targeted Radiopharmaceutical Therapy Program. Dr. Mittra received his medical and graduate degrees through the MD/PhD program at Stony Brook University. His post-graduate training included an internship at Stony Brook University, followed by a residency and fellowship in Nuclear Medicine at Stanford University where he was faculty for many years before moving to OHSU. Dr. Mittra is interested in all aspects of nuclear medicine with a focus on targeted radiopharmaceutical therapies. His research interests are focused on the translation of novel radioisotopes for imaging and therapy. He is involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the North American Neuroendocrine Tumor Society (NANETS), among others. PRRT-RELATED TOXICITIES THOR HALFDANARSON, MD Professor of Oncology Mayo Clinic College of Medicine and Science Thor Halfdanarson, MD Mayo Clinic Dr. Halfdanarson is a professor of Oncology at the Mayo Clinic College of Medicine and Science and a consultant in Medical Oncology at the Mayo Clinic. He specializes in GI oncology with a focus on NETs and cancers of unknown primary, serves as the Associate Medical Director of the Cancer Clinical Trials Office at the Mayo Clinic Comprehensive Cancer Center and is the co-chair of the Pancreatic/Neuroendocrine Tumor Board. Dr. Halfdanarson is a member of the NCCN guidelines panel for NETs, the Co-Chair of the NET Group at Alliance for Clinical Trials in Oncology and the current Vice President of NANETS.ar medicine and molecular imaging. He is the inaugural chair of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, Board Member and Treasure of the Neuroendocrine Tumor Research Foundation (NETRF), a member of The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) Board, and president of NorCal CarciNET Community, one of the largest NET patient communities in the United States. He is currently the sole patient rights advocate for the Nuclear Regulatory Commission’s Advisory Committee for the Medical Use of Isotopes (ACMUI).

PRRT Resources EDUCATIONAL WEBINARS "Understanding Alpha & The Evolving PRRT Landscape" Sep 22, 2025 Download the Presentation Slides Here >>> The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. Watch here "PRRT Nurse's Perspective: What to Expect With PRRT" March 7, 2025 Click here to download the transcript >>> Download the Presentation Slides Here >>> Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety. Watch here "What Matters About PRRT: What is PRRT & How Does it Work" - 2025 NCF Patient Conference June 20, 2025 Watch here "What Matters About PRRT: Preventing and Managing Toxicities & Latest Advances" 2025 NCF Patient Conference June 20, 2025 Watch here "Understanding PRRT" - 2024 LACNETS Neuroendocrine Tumor Patient Conference June 15, 2024 Watch here LACNETS Educational Event January 11, 2024 Learn the latest on PRRT with NET expert Dr. Jonathan Strosberg. Dr. Strosberg was the principal investigator of the NETTER-1 study which led to the FDA approval of Lutathera and has authored numerous articles on PRRT. He will discuss the latest in PRRT, including special considerations and current clinical trials. Watch here "The Latest in PRRT" with Carina Mari Aparici, MD Watch "The Latest in PRRT" with Dr. Carina Mari Aparici. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. Watch here "What's New in PRRT" with Amir Iravani, MD Nuclear Medicine Physician and Theranostics Director at Fred Hutchinson Cancer Center, Dr. Amir Iravani, shares the latest on Peptide Receptor Radionuclide Therapy (PRRT). Better understand the difference between beta and alpha PRRT, current trials and updates on PRRT for Lung NET, adolescents and dosimetry. Watch here "The Latest in NET Imaging & PRRT" with Thomas Hope, MD NET expert and radiologist Dr. Thomas Hope of UCSF addresses the latest in NET imaging and PRRT. Watch here "Future of PRRT" with Erik S. Mittra, MD, PhD Nuclear Medicine Physician Dr. Erik Mittra provides an update on PRRT. Plus, hear from a NET patient who has received multiple rounds of PRRT treatments. Watch here "Exciting Advances in NET Management: Cu64 DOTATATE & Alpha PRRT" with Ebrahim S. Delpassand, M.D., F.A.C.N.M. Nuclear medicine specialist Dr. Delpassand provides an update on the exciting advances in NET Management including Cu64 DOTATATE & Alpha PRRT. Watch here Click Here For Our Full PRRT Video Playlist READ Radioligand Therapy and Sequencing in Gastroenteropancreatic Neuroendocrine Tumors: A Patient Perspective Review This review looks at the factors that influence patients’ decisions about radioligand therapy, how they feel about when it should be used in their care, the challenges they may face in accessing this treatment, and the disparities—such as those related to race or geography—that can affect access to high-quality care. NETTER-2 Study Results: Looking Beyond The Headlines New Article: Sequencing of Somatostatin-Receptor–Based Therapies in Neuroendocrine Tumor Patients This is an excellent review article giving a thorough overview of the evidence behind somatostatin receptor targeted therapies, which includes long-acting somatostatin analogues (SSAs) octreotide LAR and lanreotide, and radiolabeled SSAs, otherwise known as PRRT. The article offers insights regarding optimal patient selection, assessment of benefit versus risk, and treatment sequencing. PRRT PATIENT/CAREGIVER STORIES Patient Story: NET Patient shares his experience with PRRT (LACNETS) Play Video Patient Story: NET Patient shares her experience with PRRT (LACNETS) Play Video Patient & Caregiver Story: NET patient & caregiver share about their experience with PRRT (LACNETS) Play Video Patient Story: NET Patient shares her experience with Alpha PRRT Play Video PRRT Patient/Caregiver Stories Watch Now Share Whole Channel This Video Facebook Twitter Pinterest Tumblr Copy Link Link Copied Share Channel Info Close PODCAST What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances. Listen here Administrative Nurse Lindy Gardner of UCLA Health answers 10 common questions about the before, during and after of PRRT. Listen here Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT. Listen here Patient advocate Josh Mailman answers ten common questions about the past, present, and future of PRRT. Listen here BLOG POSTS Read here Read here Read here READING MATERIALS “Your Guide to NETSPOT®” by Advanced Accelerator Applications Download here “Your Guide to Lutathera Treatment” by Advanced Accelerator Applications Download here Key Facts about PRRT by Advanced Accelerator Applications Download here AAA PATIENT CONNECT by Advanced Accelerator Applications Download here Detectnet Patient Brochure by Curium Download here 'Alpha Radioligand Therapy in Neuroendocrine Neoplasms: Current Landscape and Spotlight on RYZ101' Download here Explore PRRT Clinical Trials in our Clinical Trials Guide Explore NANETS NET GUIDELINES BY TOPIC 2017 (Joint with SNMMI) Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors 2020 NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy Click here for Imaging Resources This is for informational use only. Neuroendocrine Cancer Foundation is not endorsing or recommending any particular treatment or trials. Neuroendocrine Cancer Foundation encourages you to discuss your individual needs and options with your medical team. For more information about available clinical trials, go to www.clinicaltrials.gov .

Functional NETs & Symptom Management WATCH The Latest in the Management of Functional Neuroendocrine Cancers Jan 21, 2026 Join us for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), carcinoid syndrome (excess serotonin), and other hormone-related issues and symptoms. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments such as adrenal insufficiency. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. Watch EXPLORE Symptom Tracking Tool Evernote Download Here

ABOUT CURIUM "At Curium, we have a singular focus – to develop, manufacture and supply world-class radiopharmaceutical products around the globe. We strive to innovate further in nuclear diagnostics and therapies so we can enhance the lives of people with cancer." Download the Detectnet™ Brochure >>> Download the Oncology Patient Education Brochure >>> Download the Nuclear Medicine Patient Education Brochure >>> Submit Your Question for Curium 2025 ANNUAL PATIENT CONFERENCE Confirm Your Visit to the Curium Virtual Booth! First name Last name Email Submit CONTACT Jenny Yessaian RN, MBA Sr Director of Marketing C: +1.626.696.0535 111 Westport Plaza, Suite 800 St. Louis, MO 63146 This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by the Neuroendocrine Cancer Foundation. Talk to your medical team about your individual care and treatment.

See videos from the previous annual conferences of the Neuroendocrine Cancer Foundation Annual Conferences < Back to Topics 2023 Virtual LACNETS NET Patient Conference Play Video Play Video 13:08 Welcome & Introduction • 2023 LACNETS Neuroendocrine Tumor Patient Conference • June 17, 2023 The LACNETS team welcomes viewers to the 2023 LACNETS Neuroendocrine Tumor Patient Conference on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 21:51 NETS 101: Overview of NET Terms & Concepts • Dr. Aman Chauhan • 2023 LACNETS Patient Conference Watch "NETS 101: Overview of NET Terms & Concepts" with Dr. Aman Chauhan. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit, LACNETS.org. Play Video Play Video 27:33 A Conversation with Three NET Surgeons • Dr. Clarke, Dr. Gangi & Dr. Anaya • 2023 LACNETS Conference Watch 'A Conversation with Three NET Surgeons' featuring Dr. Callisia Clarke, Dr. Alexandra Gangi and Dr. Daniel Anaya Saenz. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 05:02 Kimberly Shares About Her NET Journey • 2023 LACNETS Patient Education Conference Kimberly shares her inspiring NET journey as part of the 2023 LACNETS Patient Education Conference. Play Video Play Video 04:49 Navigating Treatments • Moderators: Dr. Hendifar, Dr. Li & Mary Donlevy • 2023 LACNETS Conference Moderators of the 2023 LACNETS Patient Education Conference discuss "navigating treatments." For more information, visit LACNETS.org. Play Video Play Video 17:02 The Latest in Liver-Directed Therapy • Dr. Osmanuddin Ahmed • 2023 LACNETS Patient Conference Watch "The Latest in Liver-Directed Therapy" with Dr. Ahmed. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 19:08 The Latest in NET Imaging • Dr. Nadine Mallak • 2023 LACNETS Patient Education Conference Watch "The Latest in NET Imaging" with Dr. Nadine Mallak. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 17:55 The Latest in PRRT • Dr. Carina Mari Aparici • 2023 LACNETS Patient Education Conference Watch "The Latest in PRRT" with Dr. Carina Mari Aparici. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 08:50 Symptom Management & Clinical Trials • Moderators: Dr. Hendifar, Dr. Li & Donlevy • 2023 Conference Co-Moderators discuss "Symptom Management and Clinical Trials" during the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 06:59 Don & Beth Share Their NET Journey • 2023 LACNETS Patient Conference Don & Beth share their inspiring NET journey. For more information, visit LACNETS.org. Play Video Play Video 21:49 The Latest in Systemic Treatments & Considerations for Treatment Sequencing • Dr. Kunz • LACNETS Watch "The Latest in Systemic Treatments & Considerations for Treatment Sequencing" with Dr. Pamela Kunz. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 18:39 The Latest in NET Clinical Trials • Dr. Simron Singh • 2023 LACNETS Patient Education Conference Watch "The Latest in NET Clinical Trials" with Dr. Simron Singh. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 17:07 Clinical Trials: Why, What & How • Josh Mailman • 2023 LACNETS Patient Education Conference Watch "Clinical Trials: Why, What & How" with Josh Mailman. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 36:37 Live Q&A with NET Experts Moderated by Lisa Yen • 2023 LACNETS Patient Education Conference Watch NET Experts in this live Q&A moderated by Director of Programs and Outreach Lisa Yen. This Q&A is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 34:54 Live Q&A with NET Experts Moderated by Josh Mailman • 2023 LACNETS Patient Education Conference Watch NET Experts in this live Q&A moderated by President of NorCal CarciNET & Patient Advocate Josh Mailman. This Q&A is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 05:00 Closing • Co-Moderators & the LACNETS Team • 2023 LACNETS Conference Co-Moderators and the LACNETS Team close the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. 2022 Virtual LACNETS NET Patient Conference Play Video Play Video 10:49 01. Conference Welcome from LACNETS - 2022 LACNETS NET Patient Conference 2022 LACNETS NET Patient Conference Presented by LACNETS LACNETS Staff: Lindsey Jeu De Vine, Director of Communications Lisa Yen, NP, NBC-HWC, Program Director For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 15:24 02. Co-Moderators: Newly-Diagnosed + Conference Theme - 2022 LACNETS NET Patient Conference Conference co-moderators discuss what they would say to someone who has just been diagnosed with neuroendocrine cancer (NET), as well as the conference theme, "Empowering You to Make NET Decisions." 2022 LACNETS NET Patient Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai Lisa Yen, NP, HWC-NBC, Program & Outreach Director, LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 05:29 3. What is NET? Many NET patients find it challenging to explain their diagnosis to loved ones. To help patients and loved ones understand and explain neuroendocrine tumors (NETs), we created this short educational video with the help of NET experts and patient advocates. We hope this video serves as a helpful tool to share with your loved ones. For more information on neuroendocrine cancer, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Music by Tom Bajoras. Video produced by tvplive.com. Play Video Play Video 06:38 04. Patient Story: Treatment Decisions & Navigating Insurance - 2022 LACNETS NET Patient Conference Diagnosed in 2021 with NETs in the small bowel, NET Patient Julie shares her path to treatment in hopes of providing guidance to newly-diagnosed patients. 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 15:22 05. NET Surgery: Making Decisions & Preparing for Surgery (Dr. Clarke) - 2022 LACNETS Conference Dr. Callisia Clarke addresses surgery for neuroendocrine cancer including decision-making & preparing for surgery. Presenter: Callisia Clarke, MD Surgical Oncologist Medical College of WI 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 18:28 06. NET Testing: The What, When, How and Why (Dr. Namrata Vijayvergia) - 2022 LACNETS Conference Dr. Neena Vijayvergia addresses the what, when, how and why of NET testing. Presenter: Namrata Vijayvergia, MD Medical Oncologist, Fox Chase Cancer Center 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 04:29 07. Co-Moderators: Navigating Treatment Decisions Conference co-moderators discuss what they'd share with a NET patient who considering the many treatment options for NETs. 2022 LACNETS NET Patient Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai Lisa Yen, NP, HWC-NBC, Program & Outreach Director, LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 22:57 08. NET Treatments: Medical Therapies & Clinical Trials (Dr. Diane Reidy) - 2022 LACNETS Conference Dr. Diane Reidy-Lagunes joins us for her presentation on NET treatments, including medical therapies & clinical trials. *This presentation is also available in Spanish: lacnets.org/spanish-resources Speaker: Diane Reidy-Lagunes, MD Medical Oncologist, Memorial Sloan Kettering 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 15:21 09. The Latest in Liver Directed Therapy + Histotripsy (Dr. Osman Ahmed) - 2022 LACNETS Conference International radiologist Dr. Osman "Os" Ahmed addresses the latest in liver-directed therapy and histotripsy for neuroendocrine cancer. Speaker: Osman Ahmed, MD International Radiologist, University of Chicago 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 16:32 10. The Latest in NET Imaging & PRRT (Dr. Thomas Hope) Radiologist Dr. Thomas Hope addresses the latest in NET imaging and PRRT. Speaker: Thomas Hope, MD Radiologist, UCSF 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 04:44 11. Co-Moderators: Finding a “new normal” - 2022 LACNETS NET Conference Conference co-moderators discuss what they'd say to a NET patient who wonders how to find a “new normal” in this rollercoaster ride of living with NETs. 2022 LACNETS NET Patient Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai Lisa Yen, NP, HWC-NBC, Program & Outreach Director, LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 07:12 12. Patient Story: From Diagnosis to Patient Advocacy - 2022 LACNETS NET Patient Conference Diagnosed with neuroendocrine cancer (NET) in 2021, NET patient Michel shares how the lack of information and awareness of his uncommon diagnosis inspired him to start a patient support group in Mexico called NETs Mexico. This patient story is also available in Spanish, found here: www.LACNETS.org/spanish-resources 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 21:13 13. Managing NET Symptoms & Treatment Side Effects (Dr. Sandy Kotiah) - 2022 LACNETS Conference Dr. Sandy Kotiah addresses the management of #NET symptoms and treatment side effects. Speaker: Sandy Kotiah, MD Medical Oncologist, Mercy Medical 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 16:36 14. Best Outcomes for NETs (Dr. Julie Hallet) - 2022 LACNETS Conference Surgical oncologist Dr. Julie Hallet addresses how to achieve the best outcomes for NETs and what we know about how care is delivered. Speaker: Julie Hallet, MD, MSc, FRCSC Surgical Oncologist, Sunnybrook 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 15:11 15. Being an Engaged Patient (Josh Mailman) - 2022 LACNETS Conference NET patient advocate Josh Mailman discusses the importance of being an engaged patient. Speaker: Josh Mailman, MBA President, NorCal CarciNET Community 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 03:03 16. Co-Moderators: Q&A - The importance of being an engaged patient Conference co-moderators discuss the importance of being an engaged patient. 2022 LACNETS NET Patient Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai Lisa Yen, NP, HWC-NBC, Program & Outreach Director, LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 02:32 17. Learn Your NET Intro To help improve patient-physician communication, we are excited to share that we have developed another helpful communication tool for NET patients and caregivers called NET Intro. Your NET Intro is a downloadable wallet-sized card to help you learn to introduce yourself to someone who doesn’t yet know your NET history. Download your NET Intro card here: lacnets.org/netintro *A special thank you to LACNETS Program Director Lisa Yen and our weekly support group for helping us create this important tool for NETs. Play Video Play Video 01:02:59 18. Live Q&A with the NET Experts (All Speakers) - 2022 LACNETS Conference 8 NET experts from around the country join us for a live Q&A on neuroendocrine cancer. 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 05:28 19. Conference Closing Remarks from LACNETS - 2022 LACNETS Conference 2022 LACNETS NET Patient Conference Presented by LACNETS LACNETS Staff: Lindsey Jeu De Vine, Director of Communications Lisa Yen, NP, NBC-HWC, Program Director For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. 2021 Virtual LACNETS NET Patient Conference Play Video Play Video 09:41 1. Conference Welcome - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS LACNETS Staff: Lindsey Jeu De Vine, Director of Communications Lisa Yen, NP, NBC-HWC, Program Director For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 06:30 02. Co-Moderators discuss NET expert consultation and surgery - 2021 LACNETS Virtual Conference Conference co-moderators discuss NET expert consultation and surgery for NETs 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 04:40 03. Patient Story (Federico) - 2021 LACNETS Virtual Conference NET Patient Federico and his wife share their journey with NET. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS This video is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 30:23 04. What to Expect with a NET Expert Consultation (Dr. Soares) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Heloisa Soares, MD, PhD Medical Oncologist Huntsman Cancer Institute This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 15:08 05. To Cut or Not to Cut? Surgery for NETs (Dr. Clarke) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Callisia Clarke, MD Surgical Oncologist Medical College of WI For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 03:40 06. Co-moderators discuss treatment for NETs - LACNETS 2021 Virtual Conference Conference co-moderators discuss treatment for NETs. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 20:56 07. Surveillance, Maintenance, More Treatments (Dr. Halfdanarson) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Thorvadur (Thor) Halfdanarson, MD Medical Oncologist; Mayo Clinic For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 19:16 08. Radiation Safety with PRRT (Dr. Hope) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Tom Hope, MD Radiologist UCSF For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 17:16 09. Liver-directed Therapy (Dr. Nutting) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Charles Nutting, DO Interventional Radiologist Endovascular Consultants of Colorado For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 04:29 10. Co-moderators discuss symptom management Co-moderators discuss symptom management. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 06:00 11. Patient Story about Symptom Management (Val) - 2021 LACNETS Virtual Conference NET Patient Val shares her experience with symptom management and NETs. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 17:19 12. Symptom Management (Dr. Del Rivero) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Jaydira Del Rivero, MD Endocrinologist, Oncologist NIH This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 16:29 13. Complementary Medicine (Dr. Duma) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Narjust Duma, MD Assistant Professor & Thoracic Oncologist UW Madison This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 06:27 14. Co-moderators discuss NET Research, Advocacy & Support - 2021 LACNETS Virtual Conference Co-moderators discuss NET Research, Advocacy & Support 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 18:28 15. NET Research: What's on the Horizon? (Dr. Kunz) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Pam Kunz, MD Medical Oncologist Yale Cancer Center For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 05:40 16. Caregiver Story (Federico and Gilda) - 2021 LACNETS Virtual Conference NET caregiver Gilda shares her story about the importance of NET patient advocacy and support. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS This video is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:03:41 18. Q&A with the NET Experts (All Faculty) - 2021 LACNETS Virtual Conference Description: 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS All presenters of the 2021 LACNETS Virtual Conference. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 04:58 19. Conference Closing Remarks (Co-Moderators & LACNETS Staff) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai LACNETS Staff: Lindsey Jeu De Vine, Director of Communications Lisa Yen, NP, NBC-HWC, Program Director For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. 2020 Virtual LACNETS NET Patient Conference Play Video Play Video 42:50 Finding a NET Expert + Surgery for NETs - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: LACNETS Conference Welcome (0:00 - 5:44) Lindsey Jeu De Vine, Director of Communications, LACNETS Lisa Yen, NBC-HWC, Program Director, LACNETS "Finding a NET Expert" (5:44 - 22:25) Cindy Lovelace , Executive Director Healing NET Foundation "Surgery for NETs" (22:25 - end of video) Alexandra Gangi, MD , Surgical Oncology Cedars-Sinai Medical Center For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:17:15 "Systemic Therapy: GI, Lung, PNETS & Unknown Primary" 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: "Patient Story" (0:00 - 7:03) Eric, NET Patient "Systemic Therapy: GI NETs" (7:03 - 28:13) Dan Li, MD , Medical Oncology City of Hope "Systemic Therapy: Lung NETs" (28:13 - 52:08) Robert Ramirez, DO, FACP, Neuroendocrine & Thoracic Oncology Ochsner Medical Center "Systemic Therapy: PNETs and NETs of Unknown Primary" (52:08 - end of video) Andrew Hendifar, MD, Medical Oncology Cedars-Sinai Medical Center For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:20:02 Imaging & Role of IR (Liver-Directed Therapy) + PRRT - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: "Patient Story" (0:00 - 6:06) Mary, NET Patient "Imaging & Role of IR (Liver-Directed Therapy)" (6:06 - 43:31) Michael C. Soulen, MD , Radiology Penn Medicine "Patient & Caregiver Story" (43:31 - 50:52) Shaunie, NET Patient; Heather, NET Caregiver "PRRT" (50:52 - end of video) Erik S. Mittra, MD, PhD, Diagnostic Radiology, Nuclear Medicine Oregon Health & Science University For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 49:02 Symptom Management: Diarrhea, Hyperglycemia & Diabetes - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: "Patient Story" (0:00 - 6:30) Brent, NET Patient "Symptom Management: Diarrhea" (6:30 - 29:05) David C. Metz, MD, Gastroenterology Penn Medicine "Symptom Management: NET-related Hyperglycemia and Diabetes" (29:05 - end of video) Run Yu, MD, PhD , Endocrinology UCLA Health For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:00:23 Live Q&A with 10 NET Experts - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Q&A Panel Speakers: • Alexandra Gangi, MD , Surgical Oncology, Cedars-Sinai Medical Center • Andrew Hendifar, MD, Medical Oncology, Cedars-Sinai Medical Center • Dan Li, MD , Medical Oncology, City of Hope • David C. Metz, MD , Gastroenterology, Penn Medicine • Erik S. Mittra, MD, PhD, Diagnostic Radiology, Nuclear Medicine, Oregon Health & Science University • Robert Ramirez, DO, FACP, Neuroendocrine & Thoracic Oncology, Ochsner Medical Center • Michael C. Soulen, MD , Radiology, Penn Medicine • Run Yu, MD, PhD , Endocrinology, UCLA Health Q&A Moderators: • Josh Mailman, MBA, President, NorCal CarciNET • Lisa Yen, NP, NBC-HWC Program Director, LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. 2019 LACNETS NET Patient Conference at Cedars-Sinai Play Video Play Video 18:10 Opening: Giovanna Imbesi & Shlomo Melmed, MB, ChB - 2019 LA NET Conf Opening: Giovanna Imbesi & Shlomo Melmed, MB, ChB Shlomo Melmed, MB, ChB, FRCP, MACP Executive Vice President of Academic Affairs, Dean of the Medical Faculty and Professor of Medicine, Cedars-Sinai Medical Center Giovanna Joyce Imbesi, MBA Executive Director, LACNETS Saturday, June 8th, 2019 www.LACNETS.org Play Video Play Video 10:18 Role of Oncologist + Year in Review: Andrew Hendifar, MD (Cedars Sinai) - 2019 LA NET Conf Role of Oncologist + Year in Review Andrew Hendifar, MD Gastrointestinal Oncology, Cedars-Sinai Medical Center Play Video Play Video 11:43 Giovanna Imbesi Cedars-Sinai Patient Leadership Award - 2019 LA NET Conf Giovanna Imbesi Cedars-Sinai Patient Leadership Award Giovanna Joyce Imbesi, MBA Executive Director, LACNETS 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 19:28 NET Vitals Workshop: Daneng (Dan) Li, MD - 2019 LA NET Conf NET Vitals Workshop: Daneng (Dan) Li, MD - 2019 LA NET Conf Download NET VITALS: www.LACNETS.org/netvitals Andrew E. Hendifar, MD, MPH Gastrointestinal Oncology, Cedars-Sinai Medical Center Daneng (Dan) Li, MD Medical Oncologist, City of Hope 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 09:31 Pathology: Alberto Marchevsky, MD - 2019 LA NET Conf Pathology: Alberto Marchevsky, MD Alberto Marchevsky, MD Professor, Pathology; Director, Pulmonary and Mediastinal Pathology, Cedars-Sinai Medical Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 34:00 Surgery - Liver + Pancreas: Kambiz Kosari, MD, FACS - 2019 LA NET Conf Surgery - Liver + Pancreas: Kambiz Kosari, MD, FACS Kambiz Kosari, MD, FACS Surgeon, Cedars-Sinai Medical Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 17:47 Surgery - GI: Farin Amersi, MD - 2019 LA NET Conf Surgery - GI: Farin Amersi, MD Farin Amersi, MD Surgical Oncology, Cedars-Sinai Medical Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 19:30 Interventional Radiology: Gabriel Lipshutz, MD - 2019 LA NET Conf Interventional Radiology: Gabriel Lipshutz, MD H. Gabriel Lipshutz, MD Interventional Radiology, Cedars-Sinai Medical Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 58:21 Tumor Board + Q&A: All Faculty - 2019 LA NET Conf Tumor Board + Q&A: All Faculty 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 11:09 NET Patient & Daughter Comedic Stand-up Piece: Andie & Terry Bolt - 2019 LA NET Conf NET Patient & Daughter Comedic Stand-up Piece: Andie & Terry Bolt Andie Bolt Comedian, TV Writer/Producer, and Podcaster Terry Bolt NET Patient 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 14:49 Functional Tumors - Carcinoid Syndrome: Daniel M. Halperin, MD - 2019 LA NET Conf Functional Tumors - Carcinoid Syndrome: Daniel M. Halperin, MD Daniel M Halperin, MD Medical Oncologist and Clinical Investigator, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 31:14 Nuclear Medicine Imaging & PRRT: Louise Thomson, MD - 2019 LA NET Conf Nuclear Medicine Imaging & PRRT: Louise Thomson, MD Louise E. Thomson, MD Nuclear Medicine, Cedars-Sinai Medical Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 11:31 Genomics: Jun Gong, MD - 2019 LA NET Conf Genomics: Jun Gong, MD Jun Gong, MD Hematology/Oncology, Cedars-Sinai Medical Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 14:58 Q&A - All Faculty - 2019 LA NET Conf Q&A - All Faculty 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 21:53 Insurance for NETs: Laurie Todd, “The Insurance Warrior” - 2019 LA NET Conf Insurance for NETs: Laurie Todd, “The Insurance Warrior” 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 45:34 Patient Panel + Above & Beyond Award- 2019 LA NET Conf Patient Panel 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org 2018 Conference at UCLA Health Playlist >>> 2017 Conference at City of Hope Playlist >>> 2016 Conference at Cedars-Sinai Playlist >>> 2015 Conference at Cedars-Sinai Playlist >>> < Back to Topics Next Topic >

STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET << Back STELLAR-311: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Cancers IDENTIFIER ( ClinicalTrials.gov ) : NCT06943755 DRUG/TREATMENT : Zanzalintinib and Everolimus PHASE : 2/3 STATUS : Recruiting SPONSOR : Exelixis https://www.youtube.com/watch?v=sTWl5FZwG6k DESCRIPTION: A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors. The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc., go to STELLAR-311 Clinical Trial (Exelixis) and/or ClinicalTrials.gov to view this trial here. CONTACT: Exelixis Clinical Trials, STELLAR-311 Clinical Trial (Exelixis) EMAIL: druginfo@exelixis.com PHONE: 1-888-EXELIXIS (888-393-5494) This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. OTHER HELPFUL RESOURCES: This Exelixis study site STELLAR-311 Clinical Trial (Exelixis) includes a toll-free medical information hotline, information on the study and eligibility criteria and study sites *Please note, Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials.

NET Guidelines "Understanding NET Guidelines" with Dr. Jaydira Del Rivero Click here to download presentation slides>>> Español Guidelines for Neuroendocrine Tumor Patients by NCCN Download Here Guías ASCO (Español) Guidelines for Medical Professionals by NCCN Download Here Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline Read Here Explore More Clinical Tools & Resources Information from the American Society of Clinical Oncology (ASCO) for people with cancer, families, and caregivers Patient Information (Types of Treatment for Pancreas NET) Patient Information (Types of Treatment for GI Tract NET) NANETS Guidelines for Neuroendocrine Tumors by the North American Neuroendocrine Tumor Society Download Here To access NANETS' NET guidelines by topic, simply click on each link below. Practical Considerations when providing Palliative Care to patients with Neuroendocrine Tumors in the context of routine disease management or hospice care Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of High Grade Gastroenteropancreatic and Gynecologic Neuroendocrine Neoplasms 2021 The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma 2021 CommNETS/NANETS Guidelines for the Diagnosis and Management of Patients With Lung NETs: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines 2020 The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors 2020 The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors 2020 NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy 2019 NANETS/SNMMI Procedure Standard for Somatostatin Receptor Based Peptide Receptor Radionuclide Therapy with 177Lu-Dotatate 2017 The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society 2017 The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors 2017 (Joint with SNMMI) Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors 2013 Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors 2010 The North American Neuroendocrine Tumor Society (NANETS) Guidelines: Mission, Goals, and Process Guidelines for Neuroendocrine Tumors by the European Neuroendocrine Tumor Society (ENETS) Read Here To access the ENETS guidelines by topic, simply click on each link below. ENETS guidance paper for nonfunctioning pancreatic neuroendocrine tumours published on 5 October 2023 ENETS guidance paper for appendiceal neuroendocrine tumours published on 16 August 2023 ENETS guidance paper for functioning pancreatic NET syndromes published on 20 June 2023 ENETS guidance paper for colorectal neuroendocrine tumours published on 2 June 2023 ENETS guidance paper for gastroduodenal NET G1-G3 published on 20 May 2023 ENETS guidance paper for digestive neuroendocrine carcinoma published on 1 March 2023 ENETS guidance paper for carcinoid syndrome and carcinoid heart disease published on 25 April 2022 Gastroenteropancreatic Neuroendocrine Neoplasms: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up by the North American Neuroendocrine Tumor Society Download Here Explore the Interactive/Pocket Guideline Here

See video resources on liver-directed therapy for those with neuroendocrine cancer Liver-Directed Therapy LEARNING RESOURCES Liver Directed Therapy Liver Directed Therapy Play Video Share Whole Channel This Video Facebook Twitter Pinterest Tumblr Copy Link Link Copied Now Playing 3. Liver-Directed Therapy • Dr. Lindsay Thornton • 2025 NET Cancer Day Symposium 12:56 Play Video Now Playing 06. Liver-Directed Therapy: Killing Liver Tumors Without a Big Scar • Gregory Woodhead, MD, PhD 15:59 Play Video Now Playing Episode 38: "NEN Treatments: Focus on Liver-Directed Therapies (Part 1) 31:32 Play Video PODCAST EPISODES HISTOTRIPSY RESOURCES The company, HistoSonics, recently launched a new website – called myhistotripsy.com – to help educate patients on histotripsy and help them locate treatment sites. The website offers an overview of histotripsy and features patient stories, a form to help determine if histotripsy is right for you, and resources to find a doctor near you. Visit the Patient Website Articles on Histotripsy: "First Release #HOPE4LIVER Data Reveals 'Exciting' Potential of Histotripsy for Liver Tumours" "The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors" "HistoSonics® Publishes Results of its Pivotal #HOPE4LIVER Trials"

Diarrhea < Back to Topics Diarrhea Play Video Play Video 01:37:36 "The Latest in the Management of Functional Neuroendocrine Cancers • Jan, 2026 • Dr. Del Rivero Join this @NCFCancer educational patient event for an easy-to-understand overview of functional neuroendocrine tumors (NETs) with Dr. Jaydira Del Rivero, a medical oncologist and endocrinologist at the National Cancer Institute. Functional NETs can cause the body to produce too many hormones, leading to challenging symptoms such as low blood sugar (often seen in insulinoma), high blood sugar (glucagonoma), and other hormone-related issues. Dr. Del Rivero will explain what these syndromes are, how they’re diagnosed, and the latest updates in treatment. She will also discuss conditions that can occur because of NETs or their treatments. She will help patients understand why symptoms like hypoglycemia are more common in some NET types. Whether you’re a patient, caregiver, or simply want to better understand functional NETs, this webinar will offer practical, up-to-date information to help you feel more informed and empowered. Potential Topics: Functional NET, Hormone-producing, Insulinoma, Gastrinoma, VIPoma, Zollinger-Ellison syndrome (ZES), Carcinoid, Hypoglycemia, Diarrhea, Flushing ABOUT DR. JAYDIRA DEL RIVERO Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. For more information, visit https://www.ncf.net/events/jan2026 Play Video Play Video 01:33:48 LACNETS • "Symptom Management" with Dr. David Metz • Oct 2023 Join LACNETS to hear Neuroendocrinologist, Dr. David Metz from University of Pennsylvania discuss symptom management. The presentation will cover carcinoid syndrome, pancreatic enzymes, bile acid secretion, and short bowel syndrome. He will explain current treatments, supplements, and diets that might be helpful to control NET-related symptoms. For more information, visit LACNETS.org. Play Video Play Video 53:27 Episode 2: Diarrhea & NETs • The LACNETS Podcast ABOUT THIS EPISODE: For our second episode, NET expert and gastroenterologist Dr. David Metz answers the top 10 GI questions for NETs. Dr. Metz addresses diarrhea, diet, the difference between carcinoid tumor vs. carcinoid syndrome, and effective symptom management. MEET DR. DAVID METZ Dr. Metz is the Professor of Medicine and Co-director of the Neuroendocrine Tumor Program at the University of Pennsylvania. He is actively involved in clinical research, patient care, and teaching of students, residents, and fellows. Dr Metz’s clinical research program is particularly active in acid-peptic conditions including hypersecretory states such as Zollinger-Ellison syndrome, Helicobacter pylori infection, nonsteroidal anti-inflammatory drug gastropathy, and gastroesophageal reflux disease. He also has particular expertise in the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. He has been a principal investigator on a number of trials evaluating upper gastrointestinal disease states. He is also active in national gastroenterology societies and was a prior member of the Liason Committee for Recertification of the American Board of Internal Medicine (American Gastroenterological Association representative), the US Food and Drug Administration Gastrointestinal Drugs Advisory Committee and chair emeritus of the North American neuroendocrine Tumor Society (NANETS). Dr. Metz earned his MBBCh (MD equivalent) from the University of the Witwatersrand in Johannesburg, South Africa. He moved to the United States in 1986 and pursued a residency in internal medicine at Albert Einstein Medical Center in Philadelphia. He completed a fellowship in gastroenterology in Washington, DC, in the combined Georgetown/Veterans Affairs Medical Center/National Institutes of Health (NIH) program. He remained on staff at the NIH for 2 more years as a senior staff fellow, performing basic research in pancreatic acinar cell secretion and clinical research in Zollinger-Ellison syndrome specifically. In 1993, Dr. Metz moved to Philadelphia in the role of Assistant Professor in the clinician educator track at the University of Pennsylvania. He was promoted to Associate Professor in 1998 and Full Professor in 2003. TOP 10 QUESTIONS 1. What is the difference between carcinoid syndrome and carcinoid tumor? 2. What are the most common causes of diarrhea? How do I know if my diarrhea is from NET, medication, diet, or another reason? (What is the difference between diarrhea and fat-absorption diarrhea?") 3. How do I know if diarrhea is part of carcinoid syndrome or not? 4. Discuss cramping, bloating, and abdominal pain. Is this part of carcinoid syndrome? (How do I know if these are from the tumor, treatment, or something else?) 5. Why do they take out the gallbladder and what effect does this have on GI symptoms? 6. Are there other syndromes besides carcinoid syndrome that cause diarrhea? 7. How might my doctor evaluate my diarrhea? When should someone have EGD, colonoscopy, and capsule endoscopy and how might it affect symptom management? 8. What do I do to control my diarrhea? 9. What treatment/diet/meds would help prevent chronic cramping, bloating, loud gurgling of GI tract for a midgut patient on SSAs ? 10. What is the best diet for diarrhea? For more resources and a transcript of this episode, visit https://www.lacnets.org/podcast2. Play Video Play Video 49:02 Symptom Management: Diarrhea, Hyperglycemia & Diabetes - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: "Patient Story" (0:00 - 6:30) Brent, NET Patient "Symptom Management: Diarrhea" (6:30 - 29:05) David C. Metz, MD, Gastroenterology Penn Medicine "Symptom Management: NET-related Hyperglycemia and Diabetes" (29:05 - end of video) Run Yu, MD, PhD , Endocrinology UCLA Health For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:38:07 LACNETS Webinar: "Management of Diarrhea in NETs” with Dr. Shirley Paski Management of Diarrhea in NETs” with Dr. Shirley Paski Recorded on October 13th, 2020 Speaker: Shirley Paski, MD, IM/Gastroenterology, Cedars-Sinai Medical Center Learn more here: www.LACNETS.org Audio/Video - www.TVPlive.com < Back to Topics Next Topic >